Beris P, Muñoz M, García-Erce J A, Thomas D, Maniatis A, Van der Linden P
Haematology Service, Geneva University Hospital, Geneva, Switzerland.
Br J Anaesth. 2008 May;100(5):599-604. doi: 10.1093/bja/aen054. Epub 2008 Mar 27.
A multidisciplinary panel of physicians was convened by Network for Advancement of Transfusion Alternatives to review the evidence on the efficacy and safety of i.v. iron administration to increase haemoglobin levels and reduce blood transfusion in patients undergoing surgery, and to develop a consensus statement on perioperative use of i.v. iron as a transfusion alternative. After conducting a systematic literature search to identify the relevant studies, critical evaluation of the evidence was performed and recommendations formulated using the Grades of Recommendation Assessment, Development and Evaluation Working Group methodology. Two randomized controlled trials (RCTs) and six observational studies in orthopaedic and cardiac surgery were evaluated. Overall, there was little benefit found for the use of i.v. iron. At best, i.v. iron supplementation was found to reduce the proportion of patients requiring transfusions and the number of transfused units in observational studies in orthopaedic surgery but not in cardiac surgery. The two RCTs had serious limitations and the six observational limited by the selection of the control groups. Thus, the quality of the available evidence is considered moderate to very low. For patients undergoing orthopaedic surgery and expected to develop severe postoperative anaemia, the panel suggests i.v. iron administration during the perioperative period (weak recommendation based on moderate/low-quality evidence). For all other types of surgery, no evidence-based recommendation can be made. The panel recommends that large, prospective, RCTs be undertaken to evaluate the efficacy and safety of i.v. iron administration in surgical patients. The implementation of some general good practice points is suggested.
输血替代疗法促进网络召集了一个多学科医生小组,以审查静脉注射铁剂在接受手术的患者中提高血红蛋白水平和减少输血的疗效和安全性证据,并就围手术期使用静脉注射铁剂作为输血替代方案制定共识声明。在进行系统的文献检索以确定相关研究后,对证据进行了批判性评估,并使用推荐评估、发展和评价工作组方法制定了建议。评估了两项随机对照试验(RCT)以及骨科和心脏手术中的六项观察性研究。总体而言,静脉注射铁剂的使用几乎没有益处。在骨科手术的观察性研究中,静脉注射铁剂最多只能减少需要输血的患者比例和输血量,但在心脏手术中则不然。这两项随机对照试验存在严重局限性,六项观察性研究则受对照组选择的限制。因此,现有证据的质量被认为是中等至非常低。对于接受骨科手术且预计会出现严重术后贫血的患者,该小组建议在围手术期静脉注射铁剂(基于中等/低质量证据的弱推荐)。对于所有其他类型的手术,则无法给出基于证据的建议。该小组建议进行大型前瞻性随机对照试验,以评估静脉注射铁剂在手术患者中的疗效和安全性。还建议实施一些一般的良好实践要点。